MOUNTAIN VIEW, Calif., Nov. 13 Based on its recentanalysis of the drug eluting stents (DES) market, Frost & Sullivan recognizesBoston Scientific with the 2008 North American Frost & Sullivan MarketLeadership Award. This award highlights important milestones for BostonScientific, including FDA approvals for the PROMUS(TM) Everolimus-ElutingCoronary Stent System, the TAXUS(R) Express2(TM) Atom(TM) Stent and thecompany's second-generation TAXUS(R) Liberte(R) Stent. These product approvalsenable Boston Scientific to deliver the industry's only two-drug stentportfolio as well as the largest size matrix available and reflect on BostonScientific's commitment to delivering to patients the widest array ofsolutions in treating coronary artery disease.
The TAXUS Express2 Atom Paclitaxel-Eluting Coronary Stent System is oneexample of Boston Scientific working to expand treatment options to benefitpatients. TAXUS Atom was approved by the Food and Drug Administration (FDA) onSeptember 25, 2008, making it the first DES approved for the treatment ofsmall coronary vessels. Currently, clinicians are resigned to using eitherbare-metal stents, which pose risk of restenosis, or a partially expanded DES.The TAXUS Express2 Atom, offers clinicians a more targeted solution thatfulfills the size requirements of that anatomy, while reducing the risk ofrestenosis. That same day the FDA also announced the approval of the TAXUS(R)Express2(TM) for the treatment of in-stent restenosis in bare-metal stents.Both approvals expand indications for use for physicians and expand treatmentoptions for patients.
"Although only introduced in 2003, drug eluting stents have reshaped theentire cardiovascular industry in just a few short years," says Frost &Sullivan Research Analyst Archana Swathy. "These devices are takingpercutaneous coronary intervention to new heights, addressing many of theconcerns and issues restricting the availability of care in the past."
Data surrounding potential safety risks associated with DES and possiblelate stent thrombosis had resulted in lower usage in late 2006-07.Recognizing the importance of clinical data, Boston Scientific addressed theneed of physicians for additional DES safety information and continues toprovide effective data that reinforce its leadership position in the DESarena. Earlier this year, Boston Scientific reported encouraging one-year datafrom the SYNTAX trial that compared percutaneous coronary intervention (PCI)using the TAXUS Express2 paclitaxel-eluting coronary stent system tocontemporary coronary artery bypass graft surgery (CABG). The TAXUS stentsystems have been evaluated by the industry's most extensive randomized,controlled clinical trial program, supplemented by data on more than 35,000patients enrolled in post-approval registries. To date, approximately 4.6million TAXUS stents have been implanted globally, making them the world'smost frequently used drug-eluting stents.
In addition to its intense focus on evidence-based medicine and a robustclinical trial program, Boston Scientific has introduced the Stentplus(TM)program to enhance patient outcomes post PCI by improving patient compliancewith physician-prescribed, dual anti-platelet therapy. This comprehensiveprogram specifically targets DES patients, regardless of the stent brand.
It is endorsed by several prominent organizations, including the Societyfor Cardiovascular Angiography and Interventions (SCAI), and is used by nearly1,000 hospitals and more than 160,000 patients nationwide.
Frost & Sullivan recognizes Boston Scientific's unique capacity toestablish and sustain its leadership in this highly competitive environment,and has selected the company to be the recipient of its 2008 North AmericanMarket Leadership Award for the Drug Eluting Stents Market.
Each year, Frost & Sullivan presents this award to the company that hasdemonstrated market share leadership through the implementation of soundmarket strategy. The recipient has displayed excellence in all areas of themarket leadership process including the identification of market challenges,drivers, and restraints, as well as strategy development and methods ofaddressing these market dynamics.
Frost & Sullivan's Best Practices Awards recognize companies in a varietyof regional and global markets for demonstrating outstanding achievement andsuperior performance in areas such as leadership, technological innovation,customer service, and strategic product development. Industry analysts comparemarket participants and measure performance through in-depth interviews,analysis, and extensive secondary research in order to identify best practicesin the industry.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer ofmedical devices whose products are used in a broad range of interventionalmedical specialties. For more information, please visit:http://www.bostonscientific.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients toaccelerate their growth. The company's TEAM Research, Growth Consulting andGrowth Team Membership(TM) empower clients to create a growth-focused culturethat generates, evaluates and implements effective growth strategies. Frost &Sullivan employs over 45 years of experience in partnering with Global 1000companies, emerging businesses and the investment community from more than 30offices on six continents. For more information about Frost & Sullivan'sGrowth Partnership Services, visit http://www.awards.frost.com.Contact: Jake Wengroff 210.247.3806 firstname.lastname@example.org
SOURCE Frost & Sullivan